Sugi Predict

Sugi Predict / Compounds / SCHEMBL465345

SCHEMBL465345

SCHEMBL465345

O=S1(=O)N=NCc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CYP1A2 P05177 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ GPR3 P46089 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ TSHR P16473 2/20 0.31
▸ KEAP1 Q14145 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ NOX1 Q9Y5S8 1/20 0.30
▸ CYP2A6 P11509 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2782984 0.78 CA12 (0.39) CA12CA1CA2CA9CYP1A2
SCHEMBL2792778 0.73 ALDH1A1 (0.38) CA12CA1CA2CA9CYP1A2
SCHEMBL349152 0.72 CA12 (0.42) CA12CA1CA2CA9CYP1A2
SCHEMBL2792799 0.70 CA2 (0.40) CA12CA1CA2CA9CYP1A2
SCHEMBL7346113 0.69 CA12 (0.40) CA12CA1CA2CA9RAB9A
SCHEMBL2763395 0.67 RAB9A (0.37) CA12CA1CA2CA9RAB9A
SCHEMBL1420960 0.66 TSHR (0.42) CYP1A2TSHR
SCHEMBL29657670 0.66 TSHR (0.42) CYP1A2TSHR
SCHEMBL25456234 0.64 CACNA1H (0.32) CA12CA1CA2CA9GPR3
SCHEMBL29412548 0.63 PLAU (0.44) CA12CA1CA2CA9GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285484-A Benzothiadiazine 1, 1-dioxide compounds inhibiting HDAC6 enzyme, preparation method and application thereof 上海医药工业研究院有限公司 2023-12-26 — — CN claimed
CN-116159594-A Application of pyridinium small molecule as photocatalyst in alcohol and amine series reaction 北京理工大学 2023-05-26 — — CN claimed
CN-113121470-A Preparation method of benzothiadiazine-1, 1-dioxide compound 天津理工大学 2021-07-16 — — CN claimed
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-07-01 — — US claimed
EP-2061777-A1 BENZOÝ1,2,3¨THIADIAZINE DERIVATIVES Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-05-27 — — EP claimed
WO-2008020255-A1 BENZO[1,2,3]THIADIAZINE DERIVATIVES EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) 2008-02-21 — — WO claimed
EP-1649857-A2 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2006-04-26 — — EP claimed
US-20050054650-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 — — US claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 — — EP claimed
EP-0620813-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-10-26 — — EP claimed
WO-1993014069-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 — — WO claimed
CN-122081172-A Botrytis cinerea and application thereof in promoting plant growth and improving salt tolerance — 2026-05-26 — — CN disclosed
US-12419895-B1 Methods for treating subjects with Prader-Willi syndrome ESSENTIALIS, INC. (US) 2025-09-23 — — US disclosed
US-20250288593-A1 METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME SOLENO THERAPEUTICS, INC. 2025-09-18 — — US disclosed
US-12343348-B2 Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome ESSENTIALIS, INC. (US) 2025-07-01 — — US disclosed
EP-0127124-A2 Compounds for treating hypertension USV PHARMACEUTICAL CORPORATION (US) 1984-12-05 — — EP disclosed
EP-0121830-A2 Substituted dipeptides as antihypertensives USV PHARMACEUTICAL CORPORATION (US) 1984-10-17 — — EP disclosed
US-4184039-A Benzothiadiazine 1, 1-dioxides FINKELSTEIN PAUL 1980-01-15 — — US disclosed
US-3969518-A Inhibiting xanthine oxidase with 3-haloalkyl substituted benzothiadiazine-1,1-dioxides MERCK & CO., INC. (US) 1976-07-13 — — US disclosed
US-3892858-A Method for lowering uric acid levels using 7-alkylsufonyl substituted benzothiadiazine-1,1-dioxides MERCK & CO INC 1975-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12419895-B1 Methods for treating subjects with Prader-Willi syndrome KCNJ1, KCNJ11, KCNN1 CA12 4831/4885CA1 4746/4885CA2 2371/4885
US-20250288593-A1 METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME KCNJ1, KCNJ11, KCNN1 CA12 4831/4885CA1 4746/4885CA2 2371/4885
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES SULT2A1, TPH1, CYP1A1 CA12 3277/4885CA1 2549/4885CA2 1484/4885
US-12343348-B2 Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome KCNJ1, KCNJ11, KCNN1 CA12 4852/4885CA1 4801/4885CA2 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.